A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer
Status
RECRUITING
Phase
EARLY_PHASE1
Age
≥ 18 Years
Enrollments
20Conditions
High-risk Prostate CancerDrugs
Neoadjuvant Epigenetic TherapySummary
This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical prostatectomy. The epigenetic therapy is intended to increase the sensitivity of the underlying tumor to the patient's immune system. The platform study will evaluate safety, biomarkers, and clinical activity of an epigenetic therapy. The particular details relevant to each module within this platform study will be provided as appendices to the core protocol.
Detailed Description
The study lead investigators will modify and/or add new therapies to the protocol as data emerge from this and other trials. Participants must provide consent for archival biopsy tissue prior to surgery for prostate cancer and must consent to allowing for use of their surgical specimens from biopsy and prostatectomy for biomarker characterization. Given the absence of data in this setting, this pilot proposes this experience with up to 4 weeks of epigenetic agents at doses known to be clinically safe and effective at inducing clinical activity.
Participants will be assigned to receive one of the study interventions and will be monitored for safety and response. The duration of epigenetic therapy will be dependent on the treatment administered and will continue for the duration described in the cohort appendix for each respective combination, unless the participant: is no longer clinically benefiting (NLCB, as evidenced by symptomatic or radiographic disease progression and/or clinical deterioration); experiences any toxicity meeting specified discontinuation criteria (as described in the cohort appendix for each respective combination) or unacceptable toxicity in the best clinical discretion of the treating physician (i.e., Investigator discretion); reaches the maximum duration of study intervention; or withdraws consent.
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- Clinical Trial Recruitment Navigator
Principal Investigator
- Edwin Posadas, MD
Eligibility Criteria
Inclusion Criteria
* Men electing to undergo radical prostatectomy with preoperative tissue available.
* Age ≥18 years
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
* Adequate organ function defined by:
* AST and ALT < 2.5 x ULN
* Total bilirubin < 1.5 x ULN
* Platelets > 90 x 1000/μL
* Hemoglobin (Hgb) > 8.5 g/dL
* Serum Creatinine (Cr) <1.5 x ULN or eGFR > 30 mL/min
* People with partners of childbearing potential in circumstances that may result in the pregnancy, must have had a successful vasectomy (with medically confirmed lack of sperm that are alive) OR must either practice complete abstinence or agree to use adequate contraception (latex or synthetic condom during sexual contact with a female of childbearing potential) from the start of study treatment until 3 months following last dose of study intervention. Subjects should not donate sperm on study, during interruptions in treatment and for 3 months following completion of study drug treatment.
* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Exclusion Criteria
* Active intercurrent illness or malignancy requiring therapy outside of prostate cancer.
* Other anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization)
* Currently participating in a study using an investigational, medicinal anti-cancer agent within 4 weeks prior to first dose of epigenetic therapy.
Study Plan
Neoadjuvant Epigenetic Therapy
DRUG:
Neoadjuvant Epigenetic TherapyDescription:
Participants will be assigned to receive one of the study interventions and will be monitored for safety and response. The duration of epigenetic therapy will be dependent on the treatment administered and will continue for the duration described in the cohort appendix for each respective combination, unless the participant: is no longer clinically benefiting (NLCB, as evidenced by symptomatic or radiographic disease progression and/or clinical deterioration); experiences any toxicity meeting specified discontinuation criteria (as described in the cohort appendix for each respective combination) or unacceptable toxicity in the best clinical discretion of the treating physician (i.e., Investigator discretion); reaches the maximum duration of study intervention; or withdraws consent.
Outcome Measures
Primary Outcome Measures
Safety of Using Epigentic Therapy
Toxicity of Using Epigentic Therapy
Feasibility - % of Patients Able to Undergo Surgery
Feasibility - % of patients with grade 3/4 AEs related
Feasibility - % of patients with evaluable tissue specimens
Secondary Outcome Measures
Progression Free Survival
Timeline
Last Updated
August 17, 2025Start Date
March 21, 2025Today
December 7, 2025Completion Date ( Estimated )
February 1, 2029
Sponsors of this trial
Lead Sponsor
Edwin Posadas, MD
RECRUITING 
≥ 18 Years